GlobeNewswire·Nov 13, 2026, 5:15 PM ET

BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update

BYSI

FDA granted Fast Track designation to Plinabulin plus docetaxel for post-ICI non-squamous NSCLC patients without actionable genomic alterations.
BeyondSpring completed a strategic transaction with Biolin to fund approximately 221 of the 442 planned patients in the global DUBLIN-4 trial.
The transaction provides BeyondSpring access to clinical data generated from the China portion of the DUBLIN-4 study.
Planned interim analysis for the DUBLIN-4 trial is set for 221 progression-free survival events.
Research and development expenses for the quarter ended September 30, 2026, were $1.1 million, an increase from $1.0 million in the prior year period.
General and administrative expenses for the quarter ended September 30, 2026, were $1.0 million, compared to $0.7 million in the prior year period.
Net loss from continuing operations for the quarter ended September 30, 2026, was $2.1 million, compared to $1.6 million in the prior year period.
Cash, cash equivalents, and short-term investments stood at $0.6 million as of September 30, 2026, down from $4.0 million at December 31, 2025.
Net loss from continuing operations for the nine months ended September 30, 2026, was $5.7 million, compared to $5.8 million in the same period last year.
A gain of $53.7 million was recorded from the sale of the subsidiary Bulin, resulting in a net income attributable to BeyondSpring of $50.8 million for the quarter ended September 30, 2026.
DUBLIN-3 trial data previously published in The Lancet Respiratory Medicine showed Plinabulin plus docetaxel improved overall survival versus docetaxel alone in non-squamous NSCLC patients.

Company: BeyondSpring, Inc.
Keywords: Nasdaq:BYSI, BeyondSpring, Inc.